Greg Harrison
Stock Analyst at B of A Securities
(4.69)
# 165
Out of 5,117 analysts
104
Total ratings
62.5%
Success rate
27.77%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $34 | $28.02 | +21.34% | 9 | Dec 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $9.44 | +217.80% | 3 | Oct 27, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $507.16 | -8.71% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $37.14 | +15.78% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $39.64 | -21.80% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $12.56 | +59.24% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $75.80 | -24.80% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $462.90 | -5.38% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $400.59 | +12.33% | 6 | Aug 1, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.48 | +14.94% | 8 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $11 | $3.23 | +240.56% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $6.16 | +468.18% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $53.58 | +2.65% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $34.41 | +7.53% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $21.03 | +23.63% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $24.97 | -19.90% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.37 | +9.49% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $27.98 | +42.96% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $80.33 | -6.64% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $18.29 | -1.59% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $31.92 | -62.41% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.43 | +252.94% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.17 | +591.24% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $15.71 | -80.90% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.06 | +6,503.77% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $15.01 | +259.76% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $44.49 | +102.29% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $34
Current: $28.02
Upside: +21.34%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $9.44
Upside: +217.80%
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $507.16
Upside: -8.71%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $37.14
Upside: +15.78%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $39.64
Upside: -21.80%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $12.56
Upside: +59.24%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $75.80
Upside: -24.80%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $462.90
Upside: -5.38%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $400.59
Upside: +12.33%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.48
Upside: +14.94%
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $3.23
Upside: +240.56%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $6.16
Upside: +468.18%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $53.58
Upside: +2.65%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $34.41
Upside: +7.53%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $21.03
Upside: +23.63%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $24.97
Upside: -19.90%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.37
Upside: +9.49%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $27.98
Upside: +42.96%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $80.33
Upside: -6.64%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $18.29
Upside: -1.59%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $31.92
Upside: -62.41%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.43
Upside: +252.94%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.17
Upside: +591.24%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $15.71
Upside: -80.90%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.06
Upside: +6,503.77%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $15.01
Upside: +259.76%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $44.49
Upside: +102.29%